Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

BACKGROUND: Patients with uncontrolled type 2 diabetes mellitus (T2DM) are a priority group for intensified therapy without weight gain and with low risk of hypoglycaemia. OBJECTIVE: This study evaluates the cost effectiveness of insulin degludec plus liraglutide (IDegLira, Xultophy(®)) compared wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ericsson, Åsa, Lundqvist, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343072/
https://www.ncbi.nlm.nih.gov/pubmed/28063135
http://dx.doi.org/10.1007/s40258-016-0301-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343072/
https://www.ncbi.nlm.nih.gov/pubmed/28063135
http://dx.doi.org/10.1007/s40258-016-0301-y

Ejemplares similares